Dr. Prem Reddy Family Foundation Awards Scholarships to 85 Students Pursuing Careers in Healthcare
Empowering more than 930 students, the Foundation has committed over $2 million to the future of healthcare
VICTORVILLE, Calif., June 17, 2025--(BUSINESS WIRE)--The Dr. Prem Reddy Family Foundation presented $110,000 in academic scholarships to 85 outstanding and diverse High Desert students pursuing careers in health sciences during its annual ceremony Thursday in Victorville.
Thursday's event was the latest in the Foundation's decades-long mission to encourage and support the newest generation of healthcare professionals. To date, the Foundation has awarded more than $2 million in scholarships.
"The event was more than a celebration of achievement—it was a tribute to the passion and purpose it takes to pursue a calling in healthcare," said Sunitha Reddy, Executive Director. "These scholars are the reason this Foundation exists. Through their commitment to serve, they carry forward a legacy grounded in compassion, access, and hope."
This year's scholarship recipients ranged in age from 16 to 54, including high school students overcoming adversity and single mothers returning to school. A record number of applications were received in 2025, reflecting both increased need and interest in healthcare careers.
"You've chosen a path in healthcare, a path that demands knowledge, compassion, and resilience," said Sunitha Reddy. "As you care for others, never forget that your journey is part of a greater legacy, one rooted in service and driven by the belief that every patient deserves to be seen, heard, and healed."
Among the recipients was Tiffany Bogan, who shared her powerful personal journey. Born with neonatal abstinence syndrome and placed in foster care, she later survived Hurricane Katrina and faced continued hardship from addiction and loss in her family.
"I'm not here because everything went right—I'm here because I never gave up," Bogan said. "I've built this future from the ground up, and I plan to use it to serve others as a doctor, shaped by struggle and led by love."
The keynote address was delivered by Karyl James, Chief Nursing Officer at Desert Valley Hospital, who spoke on perseverance, purpose, and service in healthcare.
"As you stand at the crossroads of your journey in healthcare, remember that your path is not just about the destination—it's about the lives you touch, the lessons you learn, and the growth you experience along the way," she said.
Founded in 1989 by Dr. Prem Reddy, Founder, Chairman and CEO of Prime Healthcare, the Foundation supports scholarships, health education, public health programs, and community clinics locally and globally.
The list of speakers and presenters included:
Sunitha Reddy, MBA, MPH, FACHE, Executive Director of the Dr. Prem Reddy Family Foundation
Dr. Venkamma Reddy, Co-Founder of the Dr. Prem Reddy Family Foundation
Karyl James, DNP, MSN, RN, Chief Nursing Officer at Desert Valley Hospital
Tiffany Bogan, 2025 Dr. Prem Reddy Family Foundation Scholarship recipient
Elizabeth Becerra, Mayor, Victorville
Representatives and citations from the offices of U.S. Congressman Jay Obernolte, State Senator Suzette Valladares, and Assemblyman Tom Lackey
Marie Langley, MBA, FACHE, Chief Executive Officer, Desert Valley Medical Group
The High Desert is designated as a Health Professional Shortage Area, with many recipients expressing a commitment to serve locally. To address physician shortages across the Inland Empire, Dr. Reddy and the Foundation helped establish the California University of Science and Medicine (CUSM) with a contribution exceeding $80 million. CUSM graduated its first class of 62 physicians in 2022, many of whom plan to serve the region.
About the Dr. Prem Reddy Family Foundation
The Dr. Prem Reddy Family Foundation, founded by Dr. Prem Reddy and his family, has donated millions in support of health education, college scholarships, public healthcare education, and free community clinics. On a global level, the foundation supports Samaritan's Purse by donating equipment used in clinics in poverty-stricken regions around the world. The foundation also funds clean water initiatives, childhood vaccinations programs, educational grants, new medical clinics, and medical missions. For more information, visit www.premreddy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617114178/en/
Contacts
For more information about the Dr. Prem Reddy Family Foundation, please contact:Andrea Bell, Dr. Prem Reddy Family Foundation Scholarship Committee at760-381-8913 or scholarships@reddyfamilyfoundation.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 minutes ago
- Medscape
Heat, Poor Air Quality Ups Heart Attack Risk
Simultaneous exposure to ozone pollution and high temperatures significantly increases the risk for acute myocardial infarction (MI) among adults in the US, according to a recent study published in Circulation . The findings highlight the dangers of joint environmental stressors even at moderate levels and the importance of timely patient counseling. Using nationwide private insurance claims data from 2016 to 2020, researchers from Yale School of Public Health, New Haven, Connecticut, and collaborators identified 270,123 cases of acute MI in people aged 18-64 years. They found joint exposure to ground-level ozone (60 ppb) and high temperatures — roughly 90-95 °F — increased the risk for an MI by 33% compared to cooler, low-ozone days. Even under moderate conditions, such as an ozone count of 50 ppb and typical temperatures around 70 °F, the risk increased by 15%. 'The lag 0f effect means clinicians need to pay close attention to high-pollution and hot days in real time,' said Lingzhi Chu, PhD, a postdoctoral associate in the Department of Environmental Health Sciences at the Yale School of Public Health and colead author of the study 'Clinicians should emphasize to younger patients that moderate levels still pose risks' to cardiovascular health. Mary Johnson, PhD, a principal research scientist of environmental health at the Harvard T.H. Chan School of Public Health in Boston, said the findings bring much-needed attention to a younger demographic. 'This study is important because it focuses on a younger age group that is often overlooked in cardiovascular research,' said Johnson, who was not involved in the study. 'Typically, you don't think about heart attacks happening in people in the young adult category.' Johnson also noted the value of examining heat and ozone together. 'We've seen studies showing impacts from temperature and from ozone individually,' she said, 'but looking at them together, and especially looking at differences between men and women, is important.' Different Risks by Sex According to the study, women showed increased vulnerability on days with both high ozone and temperatures around 90-95 degrees, while men experienced heightened risk even when only one factor was elevated. The difference in exposure-response patterns by sex was statistically significant ( P = .016). Chu said clinicians should tailor counseling based on patient demographics. 'The sex difference that males are vulnerable to mild exposures is critical,' Chu said. 'Young men need targeted proactive counselling.' While the researchers did not assess comorbidities like hypertension or diabetes, Chu acknowledged these conditions could affect risk. 'The potential pathophysiology suggests hypertension, diabetes, or obesity may compound risks, but further research is warranted,' Chu said. Johnson said these findings should challenge assumptions in primary care because these clinicians often are the first to encounter patients of the age group studied. 'Just because you're young and healthy does not necessarily rule out the risk of a cardiac event,' she said. 'Especially if there's a combination of poor air quality and elevated temperature.' Communicating Practical Prevention Acute MI is a leading cause of morbidity and mortality globally, with approximately 800,000 cases annually in the US. Adults younger than 55 years, and particularly women, account for a growing share of acute MIs. Chu recommended several practical prevention strategies clinicians can share with patients: Adjusting the timing of outdoor activities, staying hydrated, and using cooling methods such as fans or air conditioning. She also acknowledged the challenge clinicians face in educating patients without overwhelming them. 'Clinicians may consider framing mitigation as simple behavior changes rather than drastic life changes to prevent patient overwhelm,' she said. 'Some of these simple changes — like checking air quality apps, closing windows on high-ozone days, or staying hydrated — support overall health, not just cardiovascular health.' Johnson agreed. 'While we can't individually control wildfires or ozone formation, everyone can be aware of ozone levels and temperature before going outside or doing anything physically strenuous,' she said. Health Equity Concern The study relied on data from individuals with private insurance, a limitation both Chu and Johnson acknowledged. 'That population has access to care,' Johnson said. 'But what about the uninsured or underinsured? They may be more at risk because they often live in areas with worse air quality and lack resources to adapt, like access to cooling systems or healthcare.' She added that events like sudden cardiac death may be underreported in uninsured populations. 'They don't go to the emergency room. They die before they get there,' Johnson said. 'So the real risk may actually be higher than what this study captured.' Johnson said the findings also highlight a critical shift in how clinicians should view environmental risk. 'It's accurate to say we can no longer think about air pollution and environmental risks as being linked only to chronic conditions,' said Johnson. 'There are acute consequences, too, and this study illustrates that clearly.' A study published last month in the journal Epidemiology found prolonged exposure to the particulate matter in wildfire smoke was associated with small increases in the risk for several cardiovascular diseases, especially hypertension. As climate change drives more frequent heat waves and worsens air quality, both Chu and Johnson said clinicians are on the front lines of patient education and prevention. 'Clinicians are key players in translating environmental health research into actionable prevention,' Chu said. 'This study reinforces the need to think beyond traditional risk factors.' Chu and Johnson reported no relevant financial conflicts of interest.
Entrepreneur
16 minutes ago
- Entrepreneur
Quadria Group Launches USD 300 Mn HealthQuad Fund III to Boost Healthcare Innovation
The fund includes a target corpus of USD 200 million and a USD 100 million greenshoe option, aiming to further expand its footprint in the healthcare innovation space across India and Asia. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Quadria Group, a leading healthcare-focused private equity platform, has announced the launch of HealthQuad Fund III, with a proposed fundraise of up to USD 300 million. The fund includes a target corpus of USD 200 million and a USD 100 million greenshoe option, aiming to further expand its footprint in the healthcare innovation space across India and Asia. HealthQuad Fund III follows the success of its predecessor funds, which collectively backed over 18 disruptive, tech-enabled healthcare ventures. These include names like Medikabazaar, THB, Wysa, and Redcliffe Labs, many of which have emerged as category leaders. "With Fund III, we aim to thoughtfully combine Quadria's healthcare expertise, global capital network, and institutional partnerships to build a more integrated healthcare investment platform for India," said Sunil Thakur, Co-founder and Investment Committee Member at HealthQuad. "The encouraging outcomes from Funds I and II give us the confidence to further our mission of creating both financial and social value." HealthQuad was incubated in 2016 as a distinct initiative by Quadria Group to support early-growth healthcare startups with a strong technology focus. Now, with full ownership of Fund III and its separation from former partner KOIS, Quadria is poised to build India's most influential healthcare investment franchise. "India presents one of the world's most compelling healthcare investment opportunities—driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care," said Dr Amit Varma, Co-founder and Investment Committee Member, HealthQuad. "With expanded leadership, we are better positioned than ever to deliver cross-regional value across South Asia, Southeast Asia, and the GCC." Quadria has retained most of its core investment team and plans to strengthen it further with seasoned investing, operating, and clinical professionals. The firm recently closed Quadria Capital Fund III at USD 1.07 billion, highlighting robust investor confidence. "HealthQuad is not just a fund—it's Quadria's conviction in motion," said Abrar Mir, Co-founder and Investment Committee Member. "We've built a unique platform supporting diverse healthcare models, accelerating their growth with our powerful ecosystem." Founded in 2012, Quadria Capital now manages over USD 4 billion in assets across 27 investments in India, Vietnam, Indonesia, Malaysia, and Singapore, with a mission to improve healthcare access, quality, and affordability at scale.
Medscape
28 minutes ago
- Medscape
Next-Generation Obesity Treatments Take Center Stage at ADA
The upcoming American Diabetes Association (ADA) 85th Scientific Sessions will focus on new and evolving weight-loss treatments for people with and without diabetes, along with new biological and technological approaches for managing type 1 diabetes (T1D). Late-breaking symposia will include data from trials of a once-monthly injectable for obesity treatment, a nonpeptide oral GLP-1 receptor agonist (RA), and a medication combining a GLP-1 RA with another drug designed to augment fat loss while preserving lean mass. Other new findings at the meeting include the use of a GLP-1 RA in T1D and the latest data on stem cell-derived islet cell transplantation in T1D. And always, there's much more. The meeting will take place from June 20 to 24, 2025, in Chicago. 'This year again, it will be heavily focused on obesity but more on the next generation of obesity drugs. We're progressing to therapy that may be more amenable to the patient, with less frequent dosing and greater convenience,' Marlon Pragnell, PhD, ADA's vice president of research and science, told Medscape Medical News . A major theme of the meeting, said Conference Planning Committee Chair Mark A. Atkinson, PhD, director of the University of Florida Diabetes Institute, Gainesville, Florida, will be 'after decades of making moderate impacts on both type 1 and type 2 diabetes, we are now in a position where we're moving from baby steps to big leaps, be it through technology, as well as new drugs for type 2 diabetes (T2D) and obesity. There's a very positive evolution here, but now that we have all these new tools, how do we most effectively use them?' And of course, the 'elephant in the room,' Atkinson noted, is the cost of the new approaches and access, another topic that will be addressed in several sessions. 'Cost is also a huge factor. There will be discussions about cost and cost effectiveness.' Late-breaking symposia topics include the following: Once-monthly maridebart cafraglutide (MariTide, Amgen) for the treatment of obesity in people with or without T2D — a 52-week phase 2 study : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. First report of a phase 3 radomized controlled trial of orforglipron, a small nonpeptide GLP-1 RA, as monotherapy in drug-naïve T2D with inadequate glycemic control — the ACHIEVE-1 trial: These will be the full data for Eli Lilly's investigational product, following the release of top-line results in April 2025. The potential advantages here are not just that it would be an oral GLP-1 RA but because it's a nonpeptide small molecule it could be taken regardless of food or liquid intake, it wouldn't require refrigeration, and could potentially be manufactured more cheaply than injected GLP-1 RAs. 'This is actually very exciting,' Pragnell commented. Can we improve the quality of weight loss by augmenting fat mass loss while preserving lean mass? The BELIEVE study of bimagrumab plus semaglutide: The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. Efficacy and safety of CagriSema 2.4 mg/2.4 mg in adults with overweight/obesity — the REDEFINE 1 and REDEFINE 2 clinical trials: Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. ADJUnct semaglutide treatment in T1D (ADJUST-T1D) trial outcomes: With obesity increasingly recognized as an issue in T1D, the ADJUnct study examined the impact of adding semaglutide to automated insulin delivery. This symposium will include new trial outcomes. Other late-breaking symposia will cover results of the CATALYST trial of treatment of hypercortisolism in difficult to control T2D, new data from the STRIDE trial of semaglutide in peripheral artery disease, and the full data for the SOUL trial of oral semaglutide (Rybelsus) on cardiovascular and other outcomes in people with T2D at high cardiovascular risk. And there's much more, including results from a trial called PATHWEIGH, focusing on weight management in primary care, updates on inhaled insulin, new data on Vertex's stem cell-derived transplanted islets in T1D, and the use of artificial intelligence in diabetes management. According to Atkinson, 'This year's scientific sessions will showcase cutting-edge advancements in diabetes research through a robust, data-focused program. Whether attending in person or watching on-demand, participants will have the chance to connect with top experts, take part in engaging discussions, and gain critical insights that will help shape the future of diabetes care.' Pregnall and Atkinson had no disclosures.
